Physician profile
Ki Eum
NPI 1588016414
$1,038.90
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $37.82 · 2021: $457 · 2022: $544.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $372.92 | 2020-2022 | |
| Glaxosmithkline, LLC. | $150.20 | 2021 | |
| Abbvie INC. | $145.84 | 2022 | |
| Ferring Pharmaceuticals INC. | $77.19 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $71.22 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.85 | 2021-2022 | |
| Pfizer INC. | $44.74 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $43.91 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $38.88 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $20.92 | 2022 | |
| Hikma Pharmaceuticals USA | $17.23 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ki Eum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.